Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 234

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Graphene oxide selectively targets cancer stem cells, across multiple tumor types: Implications for non-toxic cancer treatment, via “differentiation-based nano-therapy”

Open access
Fiorillo, Marco, Verre, Andrea F., Iliut, Maria, Peiris-Pagés, Maria, Ozsvari, Bela, Gandara, Ricardo, Cappello, Anna Rita, Sotgia, Federica, Vijayaraghavan, Aravind, Lisanti, Michael P.·2015·Oncotarget

Abstract

// Marco Fiorillo 1,2,3 , Andrea F. Verre 4 , Maria Iliut 4 , Maria Peiris-Pag é s 1,2 , Bela Ozsvari 1,2 , Ricardo Gandara 1,2 , Anna Rita Cappello 3 , Federica Sotgia 1,2 , Aravind Vijayaraghavan 4 and Michael P. Lisanti 1,2 1 The Manchester Centre for Cellular Metabolism (MCCM), Institute of Cancer Sciences, University of Manchester, UK 2 The Breakthrough Breast Cancer Research Unit, Institute of Cancer Sciences, University of Manchester, UK 3 The Department of Pharmacy, Health and Nutritional Sciences, The University of Calabria, Italy 4 School of Materials and National Graphene Institute, University of Manchester, UK Correspondence: Michael P. Lisanti, email: // Aravind Vijayaraghavan, email: // Keywords : nanomaterials, graphene oxide, cancer stem cells, multiple cancer types: breast, ovarian Received : January 01, 2015 Accepted : February 12, 2015 Published : February 24, 2015 Abstract Tumor-initiating cells (TICs), a.k.a. cancer stem cells (CSCs), are difficult to eradicate with conventional approaches to cancer treatment, such as chemo-therapy and radiation. As a consequence, the survival of residual CSCs is thought to drive the onset of tumor recurrence, distant metastasis, and drug-resistance, which is a significant clinical problem for the effective treatment of cancer. Thus, novel approaches to cancer therapy are needed urgently, to address this clinical need. Towards this end, here we have investigated the therapeutic potential of graphene oxide to target cancer stem cells. Graphene and its derivatives are well-known, relatively inert and potentially non-toxic nano-materials that form stable dispersions in a variety of solvents. Here, we show that graphene oxide (of both big and small flake sizes) can be used to selectively inhibit the proliferative expansion of cancer stem cells, across multiple tumor types. For this purpose, we employed the tumor-sphere assay, which functionally measures the clonal expansion of single cancer stem cells under anchorage-independent conditions. More specifically, we show that graphene oxide effectively inhibits tumor-sphere formation in multiple cell lines, across 6 different cancer types, including breast, ovarian, prostate, lung and pancreatic cancers, as well as glioblastoma (brain). In striking contrast, graphene oxide is non-toxic for “bulk” cancer cells (non-stem) and normal fibroblasts. Mechanistically, we present evidence that GO exerts its striking effects on CSCs by inhibiting several key signal transduction pathways (WNT, Notch and STAT-signaling) and thereby inducing CSC differentiation. Thus, graphene oxide may be an effective non-toxic therapeutic strategy for the eradication of cancer stem cells, via differentiation-based nano-therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.3348

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 234

Metadata

Authors
Fiorillo, M., Verre, A. F., Iliut, M., Peiris-Pagés, M., Ozsvari, B., Gandara, R., Cappello, A. R., Sotgia, F., Vijayaraghavan, A., & Lisanti, M. P.
Venue
Oncotarget
Published
2015-02-24
Volume
6
Issue
6
Pages
3553-3562
ISSN
1949-2553 (ISSN-L)
OpenAlex
W1546117988
Cited by
234
References
2
FWCI
11.17
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.